- Home
- Who We Are
About Us
Qu Biologics has attracted a team of life sciences professionals who are leaders in their respective fields.
- What We Do
What We Do
Qu Biologics’ SSIs restore innate immune function and reverse the chronic inflammation underlying many conditions such as cancer and immune-related disease.
- Clinical Trials
Clinical Trials
Investigational treatment QBECO SSI is an immunotherapy aimed at restoring normal immune function to reverse the chronic inflammation underlying Crohn’s disease.
- Partner With Us
Partner With Us
To gain a better understanding of the root causes of disease and the potential benefits of novel immunotherapies, Qu Biologics has a number of university research collaborations.
- Qu In The News
- Careers
Careers
Join a team of innovators who have a passion to make a difference. In a short time, our ambitious team has achieved a number of major milestones and we have many big goals ahead.
- Contact Us
Publications
Peer reviewed manuscripts
- Distinct inactivated bacterial-based immune modulators vary in their therapeutic efficacies for treating disease based on the organ site of pathology. Scientific Reports, (2020) April 3, Volume 10, Article number: 5901
- Novel Microbial-Based Immunotherapy Approach for Crohn’s Disease. Frontiers in Medicine, (2019) July 19
- Immune Stimulation Using a Gut Microbe-Based Immunotherapy Reduces Disease Pathology and Improves Barrier Function in Ulcerative Colitis. Frontiers in Immunology, (2018) September 27
- Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapy. OncoImmunology, (2018) Volume 7, e1398875
- Attenuating immune pathology using a microbial-based intervention in a mouse model of cigarette smoke-induced lung inflammation. Respiratory Research, (2017) Volume 18, p 92
- A novel microbe-based treatment that attenuates the inflammatory profile in a mouse model of allergic airway disease. Scientific Reports, (2016) Volume 6, Article ID 35338
- Site-Specific Immunomodulator: A Novel Treatment for Crohn’s Disease, Gastroenterology Research and Practice, (2015) Volume 2015, Article ID 231243
Scientific Abstracts and Presentations
- Novel microbial-based immunotherapy approach enables application of adoptive cell therapy for solid tumors by enhancing both immune access to tumor microenvironment and cancer cell immunogenecity. International Cancer Immunotherapy Conference (CICON) 2019, Paris, France. Poster Presentation
- Novel Escherichia coli Derived Therapeutic Immunotherapies Reduce Innate Immune Responses to Protect Muc2 deficient mice from Spontaneous Colitis. International Congress of Mucosal Immunology 2017, Washington DC. Talk and Poster Presentation
- Site-Specific Immunomodulators exploit the potent immune response to infection to effectively mobilize innate anti-tumour immunity. BioCanRx Summit for Cancer Immunotherapy 2017, Gatineau, QC. Poster Presentation
- Harnessing innate anti-tumour immunity using a Klebsiella-derived therapeutic to reduce tumour burden and improve outcomes in mouse models of lung cancer. American Association of Immunologists – Immunology 2017, Washington DC. Talk & Poster Presentation
- A Phase 1/2 Randomized, Placebo-Controlled, Double-Blind Study of the Induction of Clinical Response and Remission Using a Novel Immunotherapy (QBECO) in Subjects with Moderate To Severe Crohn’s Disease. Digestive Diseases Week 2017, Chicago IL. Poster Presentation
- Site-Specific Immunomodulators (SSIs) are Novel Immunotherapies for Cancer, The American Association of Immunologists Immunology 2016, Seattle, WA. Poster Presentation
- Clinical Trial Recruitment with Social Media – What to Expect?, Digestive Diseases Week 2016, San Diego, CA, Poster Presentation
- Anti-cancer Efficacy in a Preclinical Model of Lung Cancer Using QBKPN Site-Specific Immunomodulation, Keystone Symposia 2016, Killarney, Ireland, Poster Presentation
- Site Specific Immunomodulators (SSIs): A Novel Immunotherapy for Cancer, Canadian Cancer Immunotherapy Consortium (CCIC) Symposium 2015, Vancouver, BC, Poster Presentation
- Anti-cancer Efficacy in a Preclinical Model of Lung Cancer Using QBKPN Site Specific Immunomodulation, Canadian Cancer Immunotherapy Consortium (CCIC) Symposium 2015, Vancouver, BC, Poster Presentation
- Site Specific Immunomodulation – A Novel Therapeutic Approach for the Management of Moderate-to-Severe Crohn’s Disease, Digestive Diseases Week 2014, Chicago, Illinois, Poster Presentation